 | The Alpha variant (B.1.1.7) was a SARS-CoV-2 variant of concern. It was estimated to be 40–80% more transmissible than the wild-type SARS-CoV-2 (with most... 219 KB (18,220 words) - 23:46, 31 March 2024 |
| Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are... 228 KB (20,971 words) - 05:34, 6 May 2024 |
| Omicron (B.1.1.529) is a variant of SARS-CoV-2 first reported to the World Health Organization (WHO) by the Network for Genomics Surveillance in South... 207 KB (23,819 words) - 16:45, 15 April 2024 |
COVID-19 vaccine (redirect from Sars cov 2 vaccine) acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to... 192 KB (22,039 words) - 08:32, 3 May 2024 |
 | disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019... 285 KB (32,672 words) - 14:17, 28 April 2024 |
| COVID-19 testing (category CS1 foreign language sources (ISO 639-2)) involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main types of tests detect either the presence of the virus or... 183 KB (21,153 words) - 08:45, 17 April 2024 |
| 2020, a new SARS‑CoV‑2 variant, the Alpha variant or lineage B.1.1.7, was identified in the UK. Early results suggest protection to the variant from the... 98 KB (20,593 words) - 02:58, 8 March 2024 |
 | COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older.... 211 KB (16,862 words) - 03:56, 2 May 2024 |
| COVID-19 pandemic in Europe (category CS1 foreign language sources (ISO 639-2)) Retrieved 11 January 2021. "New COVID-19 Variant in the UK". gov.uk/government/collections/new-sars-cov-2-variant. Retrieved 11 January 2021. "Approval by... 201 KB (22,526 words) - 09:50, 28 March 2024 |
vaccine developed by Sanofi Pasteur and GSK plc. It is based on the SARS-CoV-2 Beta variant. EMA countries (as booster only) Austria Belgium Bulgaria Croatia... 318 KB (19,351 words) - 20:00, 21 April 2024 |